AUA 2014 - Prostate Cancer

Viewing 1-20 of 59 articles

#AUA14 - Multiparametric prostate MRI and MRI/ultrasound fusion biopsy in the follow-up of prostate cancer progression for men on active surveillance - Slide Presentation

#AUA14 - Poster: Multicenter validation study of a tissue epigenenic assay to predict histopathologically cancer-negative repeat prostate biopsies

#AUA14 - Poster: Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy

#AUA14 - Poster: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort

#AUA14 - Poster: Predicting radical prostatectomy outcome among men who upgrade from clinical Gleason 6 to pathologic Gleason 7

#AUA14 - Poster: Treatment practice patterns in metastatic castration-resistant prostate cancer patients prior to receiving sipuleucel-T: Data from PROCEED

#AUA14 - Poster: Further characterization of the effects of prior or no prior docetaxel therapy on CRPC patients with bone metastases receiving Ra-223 in the phase 3 ALSYMPCA trial

#AUA14 - Poster: Impact of prior endocrine therapy on clinical benefit of abiraterone acetate in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302

#AUA14 - Poster: An indirect treatment comparison and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer post chemotherapy

#AUA14 - Nadir testosterone on ADT predicts for time to castrate resistant progression: A secondary analysis of the PR-7 intermittent vs continuous ADT trial - Session Highlights

#AUA14 - Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort - Session Highlights

#AUA14 - An exploratory analysis of the Genomic Prostate Score as a predictor of local or metastatic progression in men who experience biochemical recurrence after surgery for organ-confined prostate cancer - Session Highlights

#AUA14 - Validation of a genomic classifier for predicting clinical progression following post-operative radiation therapy in high-risk prostate cancer - Session Highlights

#AUA14 - Variation of serum prostate-specific antigen levels for men with prostate cancer managed with active surveillance - Session Highlights

#AUA14 - Free serum testosterone versus total testosterone as surrogate marker for the clinical benefit of androgen suppression in prostate cancer patients - Session Highlights

#AUA14 - An indirect treatment comparison and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer post chemotherapy - Session Highlights

#AUA14 - Impact of prior endocrine therapy on clinical benefit of abiraterone acetate in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 - Session Highlights

#AUA14 - Efficacy and long-term safety analysis of study COU-AA-302: Abiraterone acetate plus prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer - Session Highlights

#AUA14 - Sipuleucel-T-induced antigen spread: immune response to prostate-specific antigen correlates with improved overall survival - Session Highlights

#AUA14 - MRI–ultrasound fusion targeted prostate biopsy: The importance of biopsying outside the MRI lesion - Session Highlights

1
2
3